Date:3/5/2009

rative expenses were $21.4 million, and as adjusted to exclude non-cash stock-based compensation expenses, non-recurring termination related costs and intellectual property litigation costs, were $19.0 million. These results compare to $23.4 million and $20.5 million, respectively, in the third quarter of 2008 and to $26.8 million and $23.5 million, respectively, in the comparable period of 2007. Importantly, we were able to achieve higher sales during 2008 on lower absolute levels of selling, general and administrative expenses as compared to 2007. - GAAP net loss and net loss per share from continuing operations for the quarter were $77.0 million and $0.90, respectively, compared to $27.9 million and $0.29 for the fourth quarter of 2007. The increase in the net loss of $49.1 million is due primarily to a write-down of goodwill recorded during the quarter. Under GAAP, circumstances that could indicate a "goodwill impairment" include significant declines in a company's share price, adverse changes or outcomes in legal or regulatory matters, technological advances that may significantly impact a company's or a partner's products or services, or unanticipated competition. Due to the continued decline in our market value in the fourth quarter of 2008 and the further negative indicators for the capital markets and the economy as a whole, we updated our impairment tests of goodwill and acquired intangible assets and concluded a further impairment had occurred in the carrying amounts of goodwill associated with both our Medical Products and Pharmaceutical Technologies segments. Accordingly, we recorded an impairment charge to goodwill, which is a non-cash accounting item, of $50.3 million in the fourth quarter of 2008, in addition to
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study